US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill extended median survival to 13.2 months in a trial of 500 patients, offering a new option after prior treatment.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
211 Articles
211 Articles
Pancreatic cancer’s once daily pill gets US FDA nod: What it means for therapy and India?
The approval validates an entire therapeutic strategy rather than a single drug. Patients with advanced cancer lived a median 13.2 months, compared with 6.7 months on chemotherapy. Now to be tested for lung and colorectal cancer
Metastatic Pancreatic Cancer Pills Approved in USFDA Approved Rasonque for Patients with Metastatic Pancreatic Cancer. A 30-day course in the US costs 39,800 dollars.
The Food and Drug Administration (FDA) approved on Wednesday a new drug for advanced pancreatic cancer, inaugurating a new era of treatment for a disease that has long been considered one of the most difficult to treat in medicine. This drug, which is taken in two pills a day, is the first of its kind and has excited both cancer specialists and patients. It is not a cure, but it is the first treatment that substantially prolongs the life of pati…
The United States on Wednesday approved a drug, Rasonque, considered by experts to be the most significant advance ever in the fight against pancreatic cancer. This tablet treatment will extend the lives of patients.
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
